Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing SurveillanceISBN: 978-0-470-22964-4
Hardcover
500 pages
November 2008
|
—Peter K.S. Siegl, Ph.D., Siegl Pharma Consulting LLC
"At a moment in health care history when public policy and the
practice of medicine are on a collision course and meta-analysis
madness threatens to derail 21st century drug development, Turner
and Durham strive to return us to the right path, the Critical
Path, brightly lit by practical advice and sound science. This is a
timely and important book."
—Peter J. Pitts, PhD, President, Center for Medicine in the
Public Interest, Former Associate Commissioner, FDA
"Professors Turner and Durham provide a forward-looking guide to
medication safety issues relevant to all classes of
pharmaceuticals. And their guidance could not be more timely. The
public and policymakers are increasingly—and
rightly—focused on safety issues at both the development and
postmarketing stages. The authors provide a synthesis of medication
safety issues that is comprehensive, accessible, and that speaks to
a wide range of health care professionals. Integrated Cardiac
Safety is an important, and welcome, work."
—Jay Campbell, JD, RPh, Executive Director, North Carolina
Board of Pharmacy